Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma

StatusNot Yet Recruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The goal of this clinical trial is to evaluate the combination of zanzalintinib (XL092) and tegavivint in advanced hepatocellular carcinoma (HCC) and Wnt pathway mutations who have progressed after at least one prior line of systemic therapy and are naïve (not previously treated with) standard of care tyrosine kinase inhibitors targeting vascular endothelial growth factor signaling.
Trial Details
NCT Number NCT07878689
Lead Sponsor University of Texas Southwestern Medical Center
Collaborators: Iterion Therapeutics, Exelixis
Conditions
(from sponsor)		 Hepatocellular Carcinoma (HCC)
Related terms Carcinoma, Hepatocellular
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov